HOME >> MEDICINE >> NEWS
Three months is too soon to judge a CML patient's response to Gleevec, researchers find

SAN DIEGO, Calif. -- Gleevec has been shown to wipe out leukemia cells in 75 percent of the chronic myeloid leukemia (CML) patients who are treated with it. What oncologists haven't known is how long patients should take Gleevec before its effectiveness can be gauged. A new study to be presented at the American Society of Hematology (ASH) 45th Annual Meeting on Monday, Dec. 8, sheds light on the question.

"This data tells us how long a patient should take Gleevec before we measure how well it's fighting the CML. This is important in helping us know when during treatment to decide if Gleevec is the best treatment or if a new approach would be better," said Brian Druker, M.D., the study's lead author. He is the JELD-WEN Chair of Leukemia Research at the OHSU Cancer Institute and an investigator of the Howard Hughes Medical Institute.

Druker studies the molecular origin of CML as a means to develop the most effective treatments. Using this approach, Druker developed Gleevec to treat CML, a malignant cancer of the bone marrow in which the body overproduces cancerous white blood cells. Gleevec targets the cancer cells while leaving normal cells unharmed, producing little or no side effects. The blood counts of virtually all CML patients treated with the drug have returned to normal.

For this study, researchers sought to determine how long Gleevec should be given to accurately gauge a patient's response. To accomplish this, they examined data from a randomized study of 553 newly diagnosed chronic phase patients comparing Gleevec, also known as imatinib, with traditional combination therapy (interferon and cytosine arabinoside).

Scientists first studied whether a CML patient's response to Gleevec is related to a patient's survival without progression of the disease. To do this, they measured the cytogenetic response, which, in this case, refers to how many bone marrow cells contain the Philadelphia chromosome. The Philadelphia c
'"/>

Contact: Rachel MacKnight
macknigh@ohsu.edu
503-494-8231
Oregon Health & Science University
6-Dec-2003


Page: 1 2 3

Related medicine news :

1. Three-year cervical cancer screening recommendations may be applicable for certain women with HIV
2. Three anti-platelet drugs used in combination are safe
3. Three out of the four million newborn babies who die each year could be saved
4. Three-year health study of teenage girls is underway at Trenton Central High School
5. Three Harvard Medical School endowed chairs named simultaneously in sleep medicine
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Three Pfizer Inc chemists win Heroes award for epilepsy treatment for children, adults
8. Three Merck chemists win Heroes of Chemistry award for major asthma treatment advance
9. Three-time Emmy Award winning actress Kathy Baker to participate in ADHD experts on call program
10. Three-month antibiotic treatment reduces risk of future heart attack
11. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2019)... ... August 17, 2019 , ... ... Fastest-Growing Private Companies—the Inc. 5000 , For the 2nd Year In a Row, ... Growth of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC (YellowTelescope, ...
(Date:8/16/2019)... N.Y. (PRWEB) , ... August 16, 2019 , ... ... and donated a custom handcrafted, one-of-a-kind children’s aircraft to Ronald McDonald House Charities ... designed to give children residents undergoing medical treatments and their family members a ...
(Date:8/15/2019)... ... August 15, 2019 , ... The ... who have been directly affected by the closure of Hahnemann University Hospital in ... during the campaign, the ASCP Foundation will be making hardship grants of up ...
(Date:8/14/2019)... CHARLOTTE, N.C. (PRWEB) , ... August 14, 2019 , ... ... growing private companies in America. This list has long-been established as a mark of ... brands including LinkedIn, Dell, and Oracle. Teguar made the list in 2015, 2016 and ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... New Hampshire-based ... heart-healthy antioxidant resveratrol, today announced an expansion of its line of CBD-infused coffees with ... mg of CBD in a 12-oz bag. , “We are excited to expand ...
Breaking Medicine News(10 mins):
(Date:8/14/2019)... ... August 13, 2019 , ... ... voted to approve a BETA version of the NCPDP Real-Time Prescription Benefit (RTPB) ... opposition, signaling strong support for the Standard from across the industry, with representation ...
(Date:8/12/2019)... ... ... Intalere, the healthcare industry leader in delivering optimal cost, quality and clinical ... The Year - Health IT category of the Pittsburgh Technology Center (PTC) 2019 Tech ... as a healthcare IT innovator in the Pittsburgh area,” said Julius Heil, President and ...
(Date:8/9/2019)... ... August 09, 2019 , ... ... Anpac Bio CEO Dr. Chris Yu to discuss their revolutionary, game-changing technology that ... screening company that has developed a novel technology based on the biophysical properties ...
Breaking Medicine Technology:
Cached News: